Farmers Trust Co. Boosts Stake in Pfizer Inc. (NYSE:PFE)
Farmers Trust Co. boosted its stake in Pfizer Inc. (NYSE:PFE) by 0.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 177,566 shares of the biopharmaceutical company’s stock after buying an additional 690 shares during the quarter. Pfizer makes up about 1.8% of Farmers Trust Co.’s holdings, making the stock its 13th biggest position. Farmers Trust Co.’s holdings in Pfizer were worth $6,957,000 as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. 1 North Wealth Services LLC purchased a new stake in Pfizer in the 3rd quarter valued at approximately $29,000. Bourgeon Capital Management LLC purchased a new stake in Pfizer in the 3rd quarter valued at approximately $32,000. Salomon & Ludwin LLC lifted its stake in Pfizer by 362.7% in the 3rd quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 700 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management purchased a new stake in Pfizer in the 3rd quarter valued at approximately $36,000. Finally, Sageworth Trust Co purchased a new stake in Pfizer in the 3rd quarter valued at approximately $44,000. 70.21% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Pfizer stock opened at $40.67 on Thursday. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $44.56. The firm has a market cap of $221.75 billion, a PE ratio of 13.56, a P/E/G ratio of 4.24 and a beta of 0.65. The business’s fifty day moving average is $38.90 and its two-hundred day moving average is $38.18. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 31st will be paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date of this dividend is Thursday, January 30th. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. Pfizer’s dividend payout ratio is currently 48.00%.
A number of equities research analysts recently issued reports on PFE shares. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Royal Bank of Canada began coverage on Pfizer in a research note on Monday, January 6th. They set an “outperform” rating and a $46.00 price target on the stock. Bank of America began coverage on Pfizer in a research note on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target on the stock. Finally, Credit Suisse Group reissued a “hold” rating and set a $41.30 price target on shares of Pfizer in a research note on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $43.41.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: VIX – Volatility Index
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.